HONZ(SZ:300086) Xin Lang Cai Jing·2025-10-31 23:30Core Insights - Kangzhi Pharmaceutical, established in 1994 and listed in 2010, is a leading children's health enterprise in China, focusing on the research and development of pediatric medicines with over 20 pediatric drug approvals [1] Financial Performance - For Q3 2025, Kangzhi Pharmaceutical reported revenue of 326 million yuan, ranking 89th out of 110 in the industry, significantly lower than the top competitor, East China Pharmaceutical, which had revenue of 32.664 billion yuan [2] - The company's net profit was -98.12 million yuan, ranking 93rd in the industry, with a stark contrast to the leading company, Hengrui Medicine, which reported a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, Kangzhi Pharmaceutical's debt-to-asset ratio was 42.86%, higher than the previous year's 38.58% and above the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 53.36%, slightly down from 53.46% year-on-year and below the industry average of 57.17% [3] Executive Compensation - The chairman, Hong Jiangtao, received a salary of 508,200 yuan in 2024, an increase of 96,300 yuan from 2023 [4] - The total compensation for the president, Hong Jiangtao, was 508,200 yuan in 2024, up from 411,900 yuan in 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 31.29% to 41,800 [5] - The average number of circulating A-shares held per shareholder decreased by 23.83% to 10,500 [5]